Zug, Switzerland – October 8, 2025 – SQ Innovation AG, a life-science company pioneering innovative solutions for the treatment of worsening heart failure, today announced the appointment of two distinguished executives to its Board of Directors: Mr. Marco van der Poel, former Chief Executive...
Press Releases
SQ Innovation Announces FDA Approval of Lasix® ONYU for Treatment of Edema in Heart Failure
Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers and payors Worsening heart failure is among the top three indications for hospitalizations in the elderly Burlington, Massachusetts, October 8, 2025 – SQ Innovation, Inc. today...
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
SQ Innovation will use Ligand’s Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.